GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CK Life Sciences International Holdings Inc (HKSE:00775) » Definitions » Capex-to-Operating-Cash-Flow

CK Life Sciences International Holdings (HKSE:00775) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is CK Life Sciences International Holdings Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CK Life Sciences International Holdings's Capital Expenditure for the six months ended in Dec. 2023 was HK$0.00 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$433.68 Mil.

Hence, CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.00.


CK Life Sciences International Holdings Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CK Life Sciences International Holdings Capex-to-Operating-Cash-Flow Chart

CK Life Sciences International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.52 0.72 0.51 0.60 0.57

CK Life Sciences International Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow falls into.



CK Life Sciences International Holdings Capex-to-Operating-Cash-Flow Calculation

CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-291.828) / 514.181
=0.57

CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 433.684
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CK Life Sciences International Holdings  (HKSE:00775) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CK Life Sciences International Holdings Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CK Life Sciences International Holdings's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CK Life Sciences International Holdings (HKSE:00775) Business Description

Traded in Other Exchanges
Address
2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG
CK Life Sciences International Holdings Inc is a biotechnology company engaged in the research & development, commercialization, and sale of health and agricultural-related products. Products developed by CK Life Sciences are categorized into the areas of human health and environmental sustainability. The company operates three core businesses, including agriculture, nutraceutical, and pharmaceutical. Its overall product portfolio involves a presence that spans North America and the Asia Pacific. The company uses mergers and acquisitions when it identifies attractive market opportunities.

CK Life Sciences International Holdings (HKSE:00775) Headlines

No Headlines